ATARA BIOTHERAPEUTICS INC (ATRA) Stock Price & Overview
NASDAQ:ATRA • US0465132068
The current stock price of ATRA is 5.04 USD. Today ATRA is down by -6.49%. In the past month the price increased by 6.94%. In the past year, price decreased by -21.88%.
ATRA Key Statistics
- Market Cap
- 36.338M
- P/E
- 2.31
- Fwd P/E
- N/A
- EPS (TTM)
- 2.18
- Dividend Yield
- N/A
ATRA Stock Performance
ATRA Stock Chart
ATRA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ATRA. When comparing the yearly performance of all stocks, ATRA is a bad performer in the overall market: 93.13% of all stocks are doing better.
ATRA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ATRA. While ATRA is still in line with the averages on profitability rating, there are concerns on its financial health.
ATRA Earnings
On March 2, 2026 ATRA reported an EPS of -0.32 and a revenue of 3.45M. The company beat EPS expectations (63.52% surprise) and beat revenue expectations (142.15% surprise).
ATRA Forecast & Estimates
11 analysts have analysed ATRA and the average price target is 9.52 USD. This implies a price increase of 88.89% is expected in the next year compared to the current price of 5.04.
For the next year, analysts expect an EPS growth of 117.88% and a revenue growth 4.9% for ATRA
ATRA Groups
Sector & Classification
ATRA Financial Highlights
Over the last trailing twelve months ATRA reported a non-GAAP Earnings per Share(EPS) of 2.18. The EPS increased by 108.46% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.4% | ||
| ROA | 77.57% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ATRA Ownership
ATRA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.84 | 417.437B | ||
| AMGN | AMGEN INC | 16.18 | 204.229B | ||
| GILD | GILEAD SCIENCES INC | 16.24 | 183.894B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.72 | 121.25B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.51 | 83.255B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.47 | 43.24B | ||
| INSM | INSMED INC | N/A | 31.965B | ||
| NTRA | NATERA INC | N/A | 28.775B | ||
| BIIB | BIOGEN INC | 12.29 | 27.876B | ||
| MRNA | MODERNA INC | N/A | 22.581B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.41 | 21.486B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.053B | ||
| EXAS | EXACT SCIENCES CORP | 308.79 | 19.749B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ATRA
Company Profile
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. The company is headquartered in Thousand Oaks, California and currently employs 38 full-time employees. The company went IPO on 2014-10-16. The firm is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
Company Info
ATARA BIOTHERAPEUTICS INC
1280 Rancho Conejo Blvd
Thousand Oaks CALIFORNIA 94080 US
CEO: Pascal Touchon
Employees: 38
Phone: 18056234211
ATARA BIOTHERAPEUTICS INC / ATRA FAQ
Can you describe the business of ATARA BIOTHERAPEUTICS INC?
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. The company is headquartered in Thousand Oaks, California and currently employs 38 full-time employees. The company went IPO on 2014-10-16. The firm is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
What is the stock price of ATARA BIOTHERAPEUTICS INC today?
The current stock price of ATRA is 5.04 USD. The price decreased by -6.49% in the last trading session.
Does ATARA BIOTHERAPEUTICS INC pay dividends?
ATRA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ATRA stock?
ATRA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How is the valuation of ATARA BIOTHERAPEUTICS INC (ATRA) based on its PE ratio?
The PE ratio for ATARA BIOTHERAPEUTICS INC (ATRA) is 2.31. This is based on the reported non-GAAP earnings per share of 2.18 and the current share price of 5.04 USD.
Should I buy ATRA stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ATRA.
Is ATARA BIOTHERAPEUTICS INC (ATRA) expected to grow?
The Revenue of ATARA BIOTHERAPEUTICS INC (ATRA) is expected to grow by 4.9% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.